All stock lists
Unlock the score
Fresenius SE & Co. KGaA (Swiss Exchange:FRE.SW)
DE · Delayed Price · Currency is CHF
Healthcare · Medical - Care Facilities
41.03-0.64 (-1.52%)
Insider Score
/ 100
FRE.SW Insider Score
Fresenius SE & Co. KGaA has a live Insider Score.
Scored on 2 qualifying trades from 2 insiders in the last 90 days.
FRE.SW Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 5.95 B | 5.83 B | 6.16 B | 5.49 B | 5.57 B | 5.68 B |
| Revenue Growth (YoY) | 6.71 % | 2.65 % | 9.33 % | 2.88 % | 2.04 % | -0.50 % |
| Cost of Revenue | 4.39 B | 4.29 B | 4.63 B | 4.19 B | 4.12 B | 4.26 B |
| Gross Profit | 1.55 B | 1.54 B | 1.52 B | 1.30 B | 1.46 B | 1.42 B |
| SG&A Expense | 760.00 M | 743.85 M | 824.00 M | 676.63 M | 738.71 M | 645.77 M |
| R&D Expense | 167.00 M | 163.19 M | 170.00 M | 159.15 M | 163.71 M | 140.60 M |
| Operating Expenses | 918.00 M | 907.03 M | 1.06 B | 835.78 M | 902.42 M | 786.38 M |
| Operating Income | 632.00 M | 629.72 M | 468.40 M | 465.43 M | 553.03 M | 630.71 M |
| Pretax Income | 535.00 M | 577.66 M | 607.00 M | 479.45 M | 490.14 M | 613.64 M |
| Tax Provision | 136.00 M | 132.15 M | 180.00 M | 116.11 M | 145.75 M | 140.60 M |
| Net Income | 382.00 M | 435.50 M | 361.00 M | 344.32 M | 329.42 M | 229.99 M |
| EPS (Basic) | 0.68 | 0.82 | 0.64 | 0.61 | 0.59 | 0.41 |
| EPS (Diluted) | 0.68 | 0.82 | 0.64 | 0.61 | 0.59 | 0.41 |
| Shares Outstanding | 561.76 M | 560.98 M | 563.24 M | 563.24 M | 563.24 M | 563.24 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.